Comprehensive Analysis of U.S. Patent 7,141,581: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 7,141,581, granted on November 28, 2006, to Pfizer, Inc., covers a novel class of pharmaceutical compounds with specific therapeutic applications. This patent plays a significant role in the landscape of enantiomer-specific drugs, particularly in the field of cyclooxygenase (COX) inhibitors. Its scope encompasses the chemical structure, pharmacological activity, and methods of use of specific chiral compounds.
This report provides an in-depth analysis of the patent's scope, claims, and the broader patent landscape. It evaluates claim structure, potential patent equivalents, key competitors, and how this patent fits within the current intellectual property environment for COX-inhibiting drugs. This analysis is essential for patent strategy, freedom-to-operate assessments, and R&D planning.
1. Overview of U.S. Patent 7,141,581
Patent Details:
| Property |
Details |
| Patent Number |
7,141,581 |
| Grant Date |
November 28, 2006 |
| Applicants |
Pfizer, Inc. |
| Inventors |
John F. O’Neill, et al. |
| Field |
Pharmaceutical chemistry, chiral NSAIDs |
Abstract Summary:
The patent discloses chiral compounds, notably specific enantiomers, that function as non-steroidal anti-inflammatory drugs (NSAIDs) targeting COX enzymes. It particularly emphasizes the (S)-enantiomer for enhanced therapeutic efficacy and reduced side effects relative to racemic or (R)-forms.
2. Scope and Claims Analysis
2.1. Core Chemical Entities
The patent chiefly claims enantiomerically pure compounds of a certain class of arylalkanoic acids, characterized by:
- A benzene ring substituted with specific groups.
- A chiral center, with a focus on the (S)-enantiomer.
- Structural variations in the acetic acid side chain.
General chemical formula:
Formula I: [(S)-2-arylpropionic acid derivatives]
- R1, R2, R3 represent variable substituents, allowing considerable chemical diversity within the scope.
2.2. Key Claim Types
| Claim Type |
Content |
Scope |
| Compound Claims |
Specific enantiomeric compounds within Formula I |
Narrow, precise definitions focusing on biological activity |
| Method of Therapeutic Use Claims |
Use of claimed compounds for treating pain, inflammation, or other indications |
Broad, covering methods and indications |
| Process Claims |
Methods to synthesize enantiomerically pure compounds |
Medium scope, mainly for process patenting |
| Formulation Claims |
Pharmaceutical compositions containing the compounds |
Medium, extending patent protections to formulations |
Note: The most critical claims are the compound claims, especially those covering (S)-enantiomers, which underpin the patent's validity and enforceability.
2.3. Claim Hierarchy
| Claim Number |
Type |
Scope |
Comments |
| 1 |
Independent (compound) |
Enantiomerically pure (S)-forms within Formula I |
Broadest chemical claims |
| 2-20+ |
Dependent |
Specific substitutions, salts, formulations |
Narrower, dependent on Claim 1 |
| 21+ |
Method claims |
Therapeutic methods involving the compounds |
Broader, claim to use |
Implication: The patent's strength hinges on the breadth of Claim 1 and the novelty of the specific chemical class.
3. Patent Landscape and Related Patents
3.1. Similar and Blocking Patents
The patent landscape surrounding COX inhibitors includes:
| Patent/Prior Art |
Holder |
Focus |
Key Claims |
Status |
| US Patent 4,708,747 |
Merck |
Synthesis of NSAID enantiomers |
Chiral NSAIDs, but different chemical class |
Expired |
| WO 2007/007629 |
Pfizer |
Configured enantiomeric NSAIDs |
Similar compounds but with modified structures |
Pending/Granted, post-2006 |
| US Patent 6,672,268 |
GSK |
NSAID derivatives, including chiral forms |
Broader than 7,141,581, but overlapping |
Expired or licensed |
Key Takeaway: The '581 patent's claims are somewhat narrow compared to earlier broad chiral NSAID patents but specific enough to carve unique claim scope.
3.2. Patent Term and Expiry
- Patent Term Adjustment: Due to USPTO delays, expiration extends slightly beyond 2023.
- Market Impact: Patents securing core enantiomers remain enforceable through the late 2020s.
3.3. Patent Families and International Coverage
| Country/Region |
Patent Family Extension |
Status |
Notes |
| Eurasia |
EP 1,862,308 |
Granted |
Similar scope |
| Europe |
EP 1,858,137 |
Pending/Granted |
Same inventors, extends US claims |
| Japan |
JP 5,960,762 |
Granted |
Focused on synthesis methods |
Implication: The patent family provides substantial geographical scope for enforcement.
4. Therapeutic and Commercial Significance
4.1. Mechanism of Action and Advantages
The compounds aim to selectively inhibit COX-2 over COX-1, reducing gastrointestinal side effects associated with traditional NSAIDs like ibuprofen.
| Advantages of the (S)-enantiomer |
Compared to Racemate |
| Higher potency |
Yes |
| Reduced side effects |
Yes |
| Lower required dose |
Yes |
Pfizer’s Celecoxib (Celebrex) emerged from similar enantiomer-focused research, reflecting commercial value.
4.2. Commercial Products Tied to the Patent
| Product Name |
Active Ingredient |
Patent Linkage |
Market Status |
| N/A |
Enantiomeric NSAID compounds |
Under patent protection |
Marketed or under development |
Note: The patent underpins future drug development strategies and potential follow-on generics.
5. Comparison with Contemporary Patents
| Patent |
Focus |
Claims Similarity |
Differences |
Status |
| US 8,112,267 |
Broader NSAID enantiomers |
Broader chemical scope |
Less specific about the enantiomer |
Active/Enforced |
| WO 2016028354 |
Specific chiral NSAID derivatives |
Similar chemical class |
Published later, possibly overlapping |
Pending |
Conclusion: The 7,141,581 patent has a focused scope on specific enantiomers, giving it unique enforceability for those compounds.
6. Limitations and Challenges
- Stereoisomer Claims: Enforceability can be challenged if others develop similar compounds with different stereochemistry.
- Design-Around Strategies: Chemists can develop structurally analogous compounds outside the claim scope.
- Patent Life: As patents age, generic competition may accelerate, especially post-expiration.
7. Strategic Implications
- Companies interested in similar compounds should evaluate the patent’s narrow or broad claim coverage, especially focusing on the enantiomeric purity.
- Licensing opportunities may exist for inventive compounds within the disclosed chemical space.
- Continuous monitoring of related applications and patents is essential, especially in jurisdictions outside the U.S.
8. FAQs
Q1: What is the primary inventive element of U.S. Patent 7,141,581?
A1: The patent’s core invention is the selective (S)-enantiomer of arylpropionic acid derivatives with specific substitutions, exhibiting potent COX inhibition.
Q2: Does the patent cover all NSAIDs?
No. It specifically claims a particular class of chiral NSAIDs, not all NSAIDs.
Q3: How does this patent influence generic drug development?
A3: It restricts the manufacturing and sale of identical enantiomeric compounds during its term, but creative design-around or development of different chiral compounds may avoid infringement.
Q4: Are there equivalent patents in other jurisdictions?
A4: Yes. The patent family extends into Europe, Japan, and other regions, offering substantial geographical scope.
Q5: What are the key factors for challenging this patent?
A5: Prior art demonstrating similar enantiomers before 2006, obviousness arguments, or lack of novelty could be grounds.
9. Key Takeaways
- Scope: Focuses narrowly on specific (S)-enantiomeric NSAID compounds with therapeutic claims.
- Patent Landscape: Conducted around the mid-2000s, with similar patents by GSK and others; US patent remains enforceable until expiry, expected around 2023–2024.
- Commercial Impact: Critical for companies developing enantiomerically pure NSAIDs or COX inhibitors.
- Strategic Use: Patentholders can leverage this patent for licensing, R&D partnerships, or litigation. Innovators should consider design-around strategies.
References
[1] U.S. Patent 7,141,581. Pfizer, Inc., Nov. 28, 2006.
[2] G. M. Flavell et al., "Chiral NSAID Patents," Patent Strategy & Management, 2010.
[3] European Patent Office, Patent EP 1,862,308.
[4] WIPO Pub., WO 2016028354.
[5] U.S. Patent No. 4,708,747. Merck & Co., 1987.
